{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:23Z","timestamp":1793090303497,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["25ZR1402337"],"award-info":[{"award-number":["25ZR1402337"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172601"],"award-info":[{"award-number":["82172601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M762049"],"award-info":[{"award-number":["2024M762049"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105566","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:34:27Z","timestamp":1787787267000},"page":"105566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PARP inhibitors and the tumor micro-environment: Bidirectional crosstalk, resistance mechanisms, and therapeutic opportunities"],"prefix":"10.1016","volume":"227","author":[{"given":"Yue","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-9479","authenticated-orcid":false,"given":"Weiwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2026.105566_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apm.13447","article-title":"Unraveling the intricacies of cancer-associated fibroblasts: a comprehensive review on metabolic reprogramming and tumor microenvironment crosstalk","volume":"132","author":"Ahuja","year":"2024","journal-title":"Apmis"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40487-021-00167-z","article-title":"An in-depth review of niraparib in ovarian cancer: mechanism of action, clinical efficacy and future directions","volume":"9","author":"Akay","year":"2021","journal-title":"Oncol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4049\/jimmunol.2001203","article-title":"Cancer-associated fibroblasts and T cells: from mechanisms to outcomes","volume":"206","author":"Baker","year":"2021","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105566_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad043","article-title":"The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors","volume":"5","author":"Beneyton","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.critrevonc.2026.105566_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384121","article-title":"Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors","volume":"15","author":"Berland","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cmet.2022.04.003","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11-\/Lkb1-deficient lung cancer","volume":"34","author":"Best","year":"2022","journal-title":"Cell. Metab."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105566_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14728222.2019.1702974","article-title":"Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors?","volume":"23","author":"B\u00f6ckelmann","year":"2019","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2026.105566_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.886170","article-title":"Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: a focus on the immune system","volume":"13","author":"Bound","year":"2022","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061392","article-title":"Alternative non-homologous end-joining: error-prone DNA repair as Cancer's Achilles' Heel","volume":"13","author":"Caracciolo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105566_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14728222.2022.2158813","article-title":"Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment","volume":"26","author":"Catalano","year":"2022","journal-title":"Expert. Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188661","article-title":"Genomic instability, inflammatory signaling and response to cancer immunotherapy","volume":"1877","author":"Chen","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105566_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416171","article-title":"PARP inhibitor inhibits the vasculogenic mimicry through a NF-\u03baB-PTX3 axis signaling in breast cancer cells","volume":"23","author":"Chivot","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105566_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081850","article-title":"Recruitment and expansion of tregs cells in the tumor environment-how to target them?","volume":"13","author":"Cinier","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol. Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105566_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105566_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105566_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105566_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102550","article-title":"Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer","volume":"298","author":"Deng","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib19","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1038\/s41467-022-32756-5","article-title":"The KU-PARP14 axis differentially regulates DNA resection at stalled replication forks by MRE11 and EXO1","volume":"13","author":"Dhoonmoon","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105566_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/2326-6066.CIR-23-0699","article-title":"Spatial Dissection of the Immune Landscape of Solid Tumors to Advance Precision Medicine","volume":"12","author":"Di Mauro","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105566_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005627","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105566_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biopha.2017.04.023","article-title":"PLOD2 in cancer research","volume":"90","author":"Du","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105566_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130000","article-title":"Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients","volume":"4","author":"Egelston","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105566_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/1541-7786.MCR-07-0377","article-title":"Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression","volume":"6","author":"Elser","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105566_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/0008-5472.CAN-23-1443","article-title":"Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer","volume":"84","author":"Fan","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-023-00495-5","article-title":"Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling","volume":"8","author":"Fang","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib29","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1038\/s41467-025-60756-8","article-title":"Nuclear deformability increases PARPi sensitivity in BRCA1-deficient cells by increasing microtubule-dependent DNA break mobility","volume":"16","author":"Faustini","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105566_bib30","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1093\/nar\/gkae317","article-title":"EXO1 and DNA2-mediated ssDNA gap expansion is essential for ATR activation and to maintain viability in BRCA1-deficient cells","volume":"52","author":"Garc\u00eda-Rodr\u00edguez","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2026.105566_bib31","article-title":"Notch signaling, hypoxia, and cancer","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/hep.32658","article-title":"NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity","volume":"78","author":"Guo","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib33","first-page":"141","article-title":"A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors","volume":"75","author":"Hage Chehade","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105566_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.741305","article-title":"Tumor-Associated Macrophages and Their Functional Transformation in the Hypoxic Tumor Microenvironment","volume":"12","author":"He","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-023-02925-5","article-title":"Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment","volume":"43","author":"Hua","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105566_bib36","article-title":"Induction of Fatty Acid Oxidation Underlies DNA Damage-Induced Cell Death and Ameliorates Obesity-Driven Chemoresistance","volume":"11","author":"Hwang","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.critrevonc.2026.105566_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.976677","article-title":"The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies","volume":"13","author":"Ileiwat","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105566_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41419-022-04912-8","article-title":"The Achilles' heel of cancer: targeting tumors via lysosome-induced immunogenic cell death","volume":"13","author":"Iulianna","year":"2022","journal-title":"Cell. Death Dis."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105566_bib39","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105566_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105566_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.critrevonc.2026.105566_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41420-025-02554-1","article-title":"The role and mechanism of fatty acid oxidation in cancer drug resistance","volume":"11","author":"Lei","year":"2025","journal-title":"Cell. Death Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41698-021-00189-w","article-title":"PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib45","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1002\/jcp.30197","article-title":"Tumor-derived exosomes in the PD-1\/PD-L1 axis: Significant regulators as well as promising clinical targets","volume":"236","author":"Liang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105566_bib46","article-title":"XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites","author":"Lin","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-025-06291-y","article-title":"New insights on anti-tumor immunity of CD8(+) T cells: cancer stem cells, tumor immune microenvironment and immunotherapy","volume":"23","author":"Lin","year":"2025","journal-title":"J. Transl. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105566_bib48","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1021\/acs.jmedchem.3c00865","article-title":"Advances in Development of Selective Antitumor Inhibitors That Target PARP-1","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105566_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105566_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo4577","article-title":"SMAD4, activated by the TCR-triggered MEK\/ERK signaling pathway, critically regulates CD8(+) T cell cytotoxic function","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105566_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103000","article-title":"The emerging role of PARP inhibitors in prostate cancer: A narrative review","volume":"140","author":"Lobianco","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105566_bib52","article-title":"Exosomal PD-L1 in cancer and other fields: recent advances and perspectives","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","article-title":"Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma","volume":"43","author":"Luo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105566_bib54","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib55","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41467-024-51667-1","article-title":"DNA polymerase \u03b1-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps","volume":"15","author":"Machacova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105566_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105566_bib57","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-05-3050","article-title":"Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis","volume":"66","author":"Martin-Oliva","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105566_bib58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2022.07.014","article-title":"cGAS\/cGAMP\/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity","volume":"174","author":"Mekers","year":"2022","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105566_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105566_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043226","article-title":"The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies","volume":"24","author":"Melaiu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105566_bib61","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.10710","article-title":"Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential","volume":"129","author":"Milosevic","year":"2024","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105566_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105566_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914956","article-title":"New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR versus c-NHEJ Engagement","volume":"24","author":"Mladenov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105566_bib64","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP Inhibitors for Breast Cancer Treatment: A Review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol."},{"issue":"8082","key":"10.1016\/j.critrevonc.2026.105566_bib65","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","article-title":"NASP modulates histone turnover to drive PARP inhibitor resistance","volume":"645","author":"Moser","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105566_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.748033","article-title":"The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination","volume":"12","author":"Nickoloff","year":"2021","journal-title":"Front. Genet."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105566_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316903","article-title":"Cellular Responses to Widespread DNA Replication Stress","volume":"24","author":"Nickoloff","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib68","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41467-025-56392-x","article-title":"MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma","volume":"16","author":"Niveau","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105566_bib69","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"Onji","year":"2022","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105566_bib70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","article-title":"Rapid Detection and Signaling of DNA Damage by PARP-1","volume":"46","author":"Pandey","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib71","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105566_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105566_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.critrevonc.2026.105566_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1133472","article-title":"Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights","volume":"11","author":"Ragupathi","year":"2023","journal-title":"Front. Cell. Dev. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41568-022-00536-4","article-title":"Biology, vulnerabilities and clinical applications of circulating tumour cells","volume":"23","author":"Ring","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105566_bib76","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022113190","article-title":"Unrepaired base excision repair intermediates in template DNA strands trigger replication fork collapse and PARP inhibitor sensitivity","volume":"42","author":"Serrano-Benitez","year":"2023","journal-title":"Embo J."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105566_bib77","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231263","article-title":"ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype","volume":"221","author":"Sharma","year":"2024","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib79","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2320951","article-title":"Lactate\/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer","volume":"13","author":"Su","year":"2024","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105566_bib80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42255-023-00781-3","article-title":"The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells","volume":"5","author":"Talwar","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.critrevonc.2026.105566_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103124","article-title":"Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine","volume":"326","author":"Tian","year":"2024","journal-title":"Adv. Colloid Interface Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105566_bib82","doi-asserted-by":"crossref","DOI":"10.4110\/in.2023.23.e41","article-title":"The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer","volume":"23","author":"Topchyan","year":"2023","journal-title":"Immune Netw."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105566_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105112","article-title":"PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling","volume":"22","author":"van Beek","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib84","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105566_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105566_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111462","article-title":"PARP-inhibition reprograms macrophages toward an anti-tumor phenotype","volume":"41","author":"Wang","year":"2022","journal-title":"Cell. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105566_bib87","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.3892\/ol.2016.5226","article-title":"PARP-1 may be involved in angiogenesis in epithelial ovarian cancer","volume":"12","author":"Wei","year":"2016","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105566_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110847","article-title":"Mitochondrial damage-associated molecular patterns trigger arginase-dependent lymphocyte immunoregulation","volume":"39","author":"Westhaver","year":"2022","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105566_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.plantsci.2021.111134","article-title":"Review: The case for studying mitochondrial function during plant cryopreservation","volume":"315","author":"Whelehan","year":"2022","journal-title":"Plant. Sci."},{"key":"10.1016\/j.critrevonc.2026.105566_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/1179554921996288","article-title":"The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors","volume":"15","author":"Wu","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105566_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009032","article-title":"PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer","volume":"12","author":"Xia","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105566_bib92","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105566_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq0414","article-title":"A two-step mechanism governing PARP1-DNA retention by PARP inhibitors","volume":"8","author":"Xue","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105566_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116783","article-title":"Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis","volume":"176","author":"Yang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105566_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114770","article-title":"Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor","volume":"163","author":"Yi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105566_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101866","article-title":"Tumor associated neutrophils governs tumor progression through an IL-10\/STAT3\/PD-L1 feedback signaling loop in lung cancer","volume":"40","author":"Zhang","year":"2024","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105566_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113995","article-title":"ATF4-SLC7A11-GSH axis mediates the acquisition of immunosuppressive properties by activated CD4(+) T cells in low arginine condition","volume":"43","author":"Zou","year":"2024","journal-title":"Cell. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:55:46Z","timestamp":1793087746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":97,"alternative-id":["S1040842826004531"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105566","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitors and the tumor micro-environment: Bidirectional crosstalk, resistance mechanisms, and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105566"}}